David Mott Leaving MedImmune

Article

Dave Mott, president and chief executive officer (CEO) of AstraZeneca’s (London, UK) biologics business unit, MedImmune (Gaithersburg, MD), has decided to leave the company at the end of July.

Dave Mott, president and chief executive officer (CEO) of AstraZeneca’s (London, UK) biologics business unit, MedImmune (Gaithersburg, MD), has decided to leave the company at the end of July. Tony Zook, CEO of AstraZeneca’s North American business and executive vice president of global marketing, has been appointed as head of MedImmune on an interim basis until a permanent successor is identified.

AstraZeneca release

Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.